Herrmann W, Schorr H, Geisel J, Riegel W
Department of Clinical Chemistry/Central Laboratory, Universitätskliniken des Saarlandes, Homburg, Germany.
Clin Chem Lab Med. 2001 Aug;39(8):739-46. doi: 10.1515/CCLM.2001.123.
Moderate hyperhomocysteinemia is very frequent in renal patients. Aside from homocysteine (HCY) itself, the metabolites methylmalonic acid (MMA) and cystathionine (CYS) supply further information about disturbances in HCY metabolism. In two groups of renal patients, transplant and hemodialysis patients, we measured HCY, MMA and CYS and evaluated their diagnostic value for impaired HCY metabolism due to vitamin deficiency and renal insufficiency. We investigated serum samples from 63 transplant patients and 38 patients undergoing hemodialysis. HCY, MMA and CYS were assayed by gas chromatography-mass spectrometry, vitamin B6 by HPLC, B12 and folate by chemiluminescence immunoassay. The determination of HCY, MMA, and CYS in renal patients provides specific information about intracellular disturbances of HCY metabolism. The frequency of increased metabolite levels in renal patients was much higher than the frequency of lowered vitamin concentrations in serum. Furthermore, the metabolite levels in transplant patients were only moderately increased, whereas they were strongly increased in patients on hemodialysis (HCY 19.2 vs. 28.8 micromol/l, MMA 292 vs. 1025 nmol/l, CYS 733 vs. 2711 nmol/l). Our findings may support the use of MMA determination in the diagnosis of vitamin B12 deficiency in renal patients. Compared to vitamin B12 deficiency, renal dysfunction itself appears to cause only a modest elevation in serum MMA. Regression analysis revealed that the moderate elevation of HCY and CYS in transplant patients is mainly a consequence of impaired remethylation of HCY to methionine with activated transsulfuration, whereas the mildly elevated MMA level is attributable to renal dysfunction. In patients on hemodialysis, all three metabolites were markedly elevated, indicating a strongly disturbed HCY metabolism. Based on a backward regression, we discovered that the HCY metabolism was strongly disturbed by renal insufficiency and vitamin deficiency. The markedly elevated HCY level was mainly attributable to functional vitamin B12 deficiency indicated by high MMA, and the strong CYS elevation was due to renal dysfunction and inhibition of this pathway by low levels of vitamin B6. In conclusion, besides HCY, the determination of MMA and CYS levels supports an early diagnosis of B-vitamin deficiency in renal patients. MMA is a more sensitive indicator of intracellular vitamin B12 deficiency than vitamin B12 in serum.
中度高同型半胱氨酸血症在肾病患者中非常常见。除了同型半胱氨酸(HCY)本身外,代谢产物甲基丙二酸(MMA)和胱硫醚(CYS)还能提供有关HCY代谢紊乱的更多信息。在两组肾病患者,即移植患者和血液透析患者中,我们测量了HCY、MMA和CYS,并评估了它们对因维生素缺乏和肾功能不全导致的HCY代谢受损的诊断价值。我们调查了63例移植患者和38例接受血液透析患者的血清样本。采用气相色谱-质谱法检测HCY、MMA和CYS,采用高效液相色谱法检测维生素B6,采用化学发光免疫分析法检测维生素B12和叶酸。测定肾病患者的HCY、MMA和CYS可提供有关HCY细胞内代谢紊乱的具体信息。肾病患者代谢产物水平升高的频率远高于血清中维生素浓度降低的频率。此外,移植患者的代谢产物水平仅中度升高,而血液透析患者则显著升高(HCY分别为19.2和28.8微摩尔/升,MMA分别为292和1025纳摩尔/升,CYS分别为733和2711纳摩尔/升)。我们的研究结果可能支持将MMA测定用于肾病患者维生素B12缺乏的诊断。与维生素B12缺乏相比,肾功能不全本身似乎仅导致血清MMA适度升高。回归分析显示,移植患者HCY和CYS的中度升高主要是由于HCY甲基化重新生成蛋氨酸的过程受损以及转硫途径激活,而MMA水平轻度升高则归因于肾功能不全。在血液透析患者中,所有三种代谢产物均显著升高,表明HCY代谢严重紊乱。基于向后回归分析,我们发现肾功能不全和维生素缺乏会严重干扰HCY代谢。HCY水平显著升高主要归因于高MMA所提示的功能性维生素B12缺乏,而CYS的强烈升高则是由于肾功能不全以及低水平维生素B6对该途径的抑制。总之,除了HCY外,测定MMA和CYS水平有助于早期诊断肾病患者的B族维生素缺乏。MMA是细胞内维生素B12缺乏比血清维生素B12更敏感的指标。